Tenofovir alafenamide fumarate-Reference-Cited by-同舟云学术

Tenofovir alafenamide fumarate

Published:2022-03-07 Issue:2 Volume:27 Page:135965352110676
ISSN:1359-6535
Container-title:Antiviral Therapy
language:en
Short-container-title:Antiviral Therapy

Author:

Lee William A¹^ORCID,Cheng Andrew K²

Affiliation:

1. San Francisco, CA, USA

2. Akero Therapeutics, South San Francisco, CA, USA

Abstract

Tenofovir alafenamide fumarate is a lipophilic prodrug of tenofovir which is preferentially metabolized in lymphatic tissue resulting in high concentrations of tenofovir (TFV) and its active diphosphate metabolite inside the cells that replicate HIV. Due to its selectivity for these tissues, lower total doses of TAF can be administered relative to tenofovir disoproxil fumarate (TDF) which results in improved bone and renal biomarkers. Tenofovir alafenamide fumarate has become the “backbone” of multiple combination products for the treatment of HIV, combined with emtricitabine for PreP and as a monotherapy for the treatment or HBV.

Publisher

SAGE Publications

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

http://journals.sagepub.com/doi/pdf/10.1177/13596535211067600

Reference30 articles.

1. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine

2. Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue

3. Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases

4. Assessment of Mitochondrial Toxicity in Human Cells Treated with Tenofovir: Comparison with Other Nucleoside Reverse Transcriptase Inhibitors

5. Intracellular Pharmacokinetics of Tenofovir Diphosphate, Carbovir Triphosphate, and Lamivudine Triphosphate in Patients Receiving Triple-Nucleoside Regimens

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leveraging Strengths of green chromatography in Developing eco-friendly HPLC and HPTLC methods for the simultaneous analysis of Lamivudine, Dolutegravir and tenofovir alafenamide;Microchemical Journal;2024-09

2. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women;New England Journal of Medicine;2024-07-24

3. The landscape of small-molecule prodrugs;Nature Reviews Drug Discovery;2024-04-02

4. Weekly Oral Tenofovir Alafenamide Protects Macaques from Vaginal and Rectal Simian HIV Infection;Pharmaceutics;2024-03-11

5. Post delivery withdrawal time of tenofovir for blocking mother to child transmission of HBV in women with high HBV load during late pregnancy;Tropical Journal of Pharmaceutical Research;2024-01-10